☆ 4.5 Article

Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases

INFLAMMATORY BOWEL DISEASES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review Gastroenterology & Hepatology

Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases

Hongsheng Yang et al.

Summary: Ustekinumab is effective in treating CD and UC, with a risk of LOR and dose escalation of 21% and 25% respectively in CD patients. After dose escalation, 58% of patients regain clinical response. Limited data is available for LOR in UC patients, but dose escalation has shown a risk of 18% and a remission rate of 58%.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease

Yushan Pan et al.

Summary: Data on therapeutic drug monitoring in postoperative Crohn's disease are limited. This study found that higher concentrations of tumor necrosis factor antagonists were associated with improved outcomes, while ustekinumab concentrations did not show a relationship with outcomes.

INFLAMMATORY BOWEL DISEASES (2022)

添加到收藏夹
Article Gastroenterology & Hepatology

Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy

Uri Kopylov et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹
Article Gastroenterology & Hepatology

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

Omoniyi J. Adedokun et al.

GASTROENTEROLOGY (2018)

添加到收藏夹
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.